Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5272528
Max Phase: Preclinical
Molecular Formula: C38H47N5O6
Molecular Weight: 669.82
Associated Items:
ID: ALA5272528
Max Phase: Preclinical
Molecular Formula: C38H47N5O6
Molecular Weight: 669.82
Associated Items:
Canonical SMILES: C=CC(=O)NCCCC[C@H](NC(=O)OCc1ccccc1)C(=O)N1CCN(C(=O)[C@H](CC(C)C)NC(=O)c2cccc3ccccc23)CC1
Standard InChI: InChI=1S/C38H47N5O6/c1-4-34(44)39-20-11-10-19-32(41-38(48)49-26-28-13-6-5-7-14-28)36(46)42-21-23-43(24-22-42)37(47)33(25-27(2)3)40-35(45)31-18-12-16-29-15-8-9-17-30(29)31/h4-9,12-18,27,32-33H,1,10-11,19-26H2,2-3H3,(H,39,44)(H,40,45)(H,41,48)/t32-,33-/m0/s1
Standard InChI Key: ONDWZKGQCUICRL-LQJZCPKCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 669.82 | Molecular Weight (Monoisotopic): 669.3526 | AlogP: 4.42 | #Rotatable Bonds: 15 |
Polar Surface Area: 137.15 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.50 | CX Basic pKa: | CX LogP: 4.30 | CX LogD: 4.30 |
Aromatic Rings: 3 | Heavy Atoms: 49 | QED Weighted: 0.16 | Np Likeness Score: -0.49 |
1. Cundy NJ, Arciszewski J, Gates EWJ, Acton SL, Passley KD, Awoonor-Williams E, Boyd EK, Xu N, Pierson É, Fernandez-Ansieta C, Albert MR, McNeil NMR, Adhikary G, Eckert RL, Keillor JW.. (2023) Novel irreversible peptidic inhibitors of transglutaminase 2., 14 (2.0): [PMID:36846375] [10.1039/d2md00417h] |
Source(1):